Declining operating margins, shareholder dilution, and negative earnings-per-share growth drive the bearish narrative for Coinbase. Will the correction continue?
Full FDA approval for one of its drugs, an excellent earnings report, and a deep pipeline support the bullish trend. Is there more room to the upside for Amgen?